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Oxaliplatin-induced neurotoxicity (OIN) is a common complication of chemotherapy without effective
treatment. In order to clarify the mechanisms of both acute and chronic OIN, we used an ex-vivo mouse
sciatic nerve model. Exposure to 25 mM oxaliplatin caused a marked prolongation in the duration of the
nerve evoked compound action potential (CAP) by nearly 1200% within 300 min while amplitude
remained constant for over 20 h. This oxaliplatin effect was almost completely reversed by the gap
junction (GJ) inhibitor octanol in a concentration-dependent manner. Further GJ blockers showed similar
effects although with a narrower therapeutic window. To clarify the target molecule we studied sciatic
nerves from connexin32 (Cx32) and Cx29 knockout (KO) mice. The oxaliplatin effect and neuroprotection
by octanol partially persisted in Cx29 better than in Cx32 KO nerves, suggesting that oxaliplatin affects
both, but Cx32 GJ channels more than Cx29 hemichannels. Oxaliplatin also accelerated neurobiotin
uptake in HeLa cells expressing the human ortholog of Cx29, Cx31.3, as well as dye transfer between cells
expressing the human Cx32, and this effect was blocked by octanol. Oxaliplatin caused no morphological
changes initially (up to 3 h of exposure), but prolonged nerve exposure caused juxtaparonodal axonal
edema, which was prevented by octanol. Our study indicates that oxaliplatin causes forced opening of
Cx32 channels and Cx29 hemichannels in peripheral myelinated ﬁbers leading to disruption of axonal Kþ
homeostasis. The GJ blocker octanol prevents OIN at very low concentrations and should be further
studied as a neuroprotectant.
© 2015 Elsevier Ltd. All rights reserved.1. Introduction
Oxaliplatin is used extensively as a ﬁrst-line drug in gastroin-
testinal cancer chemotherapy, in particular metastatic colorectal
cancer (Andre et al., 2004). The major dose-limiting toxicity of
oxaliplatin is peripheral neuropathy that can manifest in over 60%
of treated patients. Oxaliplatin-induced neurotoxicity (OIN) can
present both as an acute or as chronic neuropathy. Acute OIN
manifestations are characterized by peripheral nerve hyperexcit-
ability symptoms, including cold-induced perioral ory, The Cyprus Institute of
enue, P.O. Box 23462, 1683,
392786.pharyngolaryngeal dysesthesias (Kweekel et al., 2005; Park et al.,
2009). The origin of OIN and hyperexcitability symptoms remains
controversial, although a variety of mechanisms have been pro-
posed. Several studies implicated the involvement of voltage-gated
potassium channels (VGKCs) (Benoit et al., 2006; Kagiava et al.,
2008; Lang et al., 2008; Sittl et al., 2010; Nodera et al., 2011;
Dimitrov and Dimitrova, 2012; Kagiava et al., 2013), others
focused on voltage-gated sodium channels (VGNaCs) (Adelsberger
et al., 2000; Webster et al., 2005; Krishnan et al., 2006; Park
et al., 2011; Argyriou et al., 2013) and some attributed OIN to
oxalate, a well-known chelator of both intracellular calcium and
magnesium, that is liberated by oxaliplatin (Grolleau et al., 2001;
Hochster et al., 2007; Sakurai et al., 2009; Tatsushima et al.,
2013). However, none of the proposed mechanisms has so far
provided a deﬁnite solution to understanding the pathogenesis of
OIN as a basis for offering effective prevention and treatment
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Ferrier et al., 2013; Loprinzi et al., 2014).
Our previous ex vivo studies on the isolated rat sciatic nerve
exposed to oxaliplatin suggested that the physiological correlate of
OIN is a form of a post-stimulus severe broadening of the repolar-
ising phase of the evoked nerve compound action potential (CAP),
called here the “oxaliplatin-effect”, which developed in a concen-
tration- and time-dependent manner (Kagiava et al., 2008).
Moreover, in the same nerve preparation, intra-axonal recordings
from nerve ﬁbers exposed to oxaliplatin have shown that hyper-
excitability occurs either as a repetitive ﬁring, or as a 400% broad-
ening of the repolarising phase of the CAP, while the resting
membrane potential of the axon remains unaffected (Kagiava et al.,
2013). Such an effect is unique in the pharmacology of the adult
mammalian axons and has been shown only once in intra-axonal
recordings from nerve ﬁbers of young rats, with relatively thin
myelin, treated with 4-aminopyridine (4-AP), a well-known VGKC
blocker (Kocsis et al., 1987). However, 4-AP or tetraethylammonium
(TEA) had no effect on adult myelinated nerve ﬁbers (Kagiava et al.,
2008).
Despite our previous ex vivo studies and reports from several
other laboratories indicating that VGKCs dysfunction could play a
role in OIN, VGKCs are unlikely to be the primary target because
patch-clamp studies failed to show any binding of oxaliplatin on
Shaker-type Kv1.1/1.2 (Broomand et al., 2009). Since these VGKCs
are responsible for the repolarizing phase of the action potential
(Kocsis et al., 1987; Chiu, 1991; Zhou et al., 1999), which is drasti-
cally affected by oxaliplatin, we hypothesized that oxaliplatin may
affect a functionally closely related target, leading indirectly to
VGKC dysfunction. Particularly relevant as potential targets appear
to be the gap junction (GJ) channels and hemichannels in the
myelin sheath, which are thought to play a crucial role in the
removal of excess Kþ from the periaxonal space through the myelin
layers. Hemichannels formed by connexin29 (Cx29, the human
ortholog is Cx31.3) at the innermost myelin membrane surround-
ing the juxtaparanodal regions, directly appose axonal VGKCs and
likely participate in the regulation of Kþ during the generation of an
action potential (Altevogt et al., 2002; Sargiannidou et al., 2008).
Due to this striking proximity to Kv1.1/1.2 VGKCs, Cx29 hemi-
channels have been proposed to open and allow the transport into
Schwann cell cytoplasm of surplus Kþ released from the axonal
juxtaparanodal region during the action potential that would
otherwise accumulate in the periaxonal space (Konishi, 1990; Chiu,
1991; Altevogt et al., 2002). Since Cx29 hemichannels are only
found in the innermost myelin layers, this functional pathway for
the regulation of Kþ likely also involves Cx32 GJ channels that
provide a passage through the entire myelin sheath reaching the
abaxonal Schwann cell cytoplasm (Scherer et al., 1995; Balice-
Gordon et al., 1998; Kleopa, 2011).
The proposed role of Cx29 hemichannels and Cx32 GJ channels
functioning together to provide a mechanism for preserving the
homeostasis of Kþ ions suggests that theymay be involved in OIN as
well. It has already been shown that the action of oxaliplatin occurs
only in myelinated ﬁbers, since oxaliplatin induced bursts of action
potentials in myelinated A-ﬁbers, but not in unmyelinated C-ﬁbers
(Sittl et al., 2010). Additionally, recent studies have shown that
oxaliplatin can affect the expression levels of GJs in astrocytes
(Yoon et al., 2013) and dorsal root ganglia (DRG) satellite glial cells
(Warwick and Hanani, 2013), while GJ blockage by carbenoxolone
results in analgesic-like effects (Rouach et al., 2003; Vessey et al.,
2004). Furthermore, GJ hemichannel blockade was found to be
neuroprotective in some cases of global cerebral ischemia in near-
term fetal sheep (Davidson et al., 2014), while gap junctional
communication could counteract the effects of the anti-tumor
agent cisplatin (homologous to oxaliplatin) (Broomand et al.,2009). Recent studies of taxol and oxaliplatin neurotoxicity
suggested that GJ blockers may have potential in treating
chemotherapy-induced neuropathic pain (Warwick and Hanani,
2013). However, none of these studies has focused on connexins
expressed in peripheral myelinated ﬁbers, where oxaliplatin causes
most pathological changes (Burakgazi et al., 2011; Krøigård et al.,
2014).
Here, we report the detailed electrophysiological and morpho-
logical correlates of OIN in the ex vivo sciatic nerve preparation and
provide evidence that OIN is mediated by Cx32 GJ channels and
Cx29/Cx31.3 GJ hemichannels in myelinated ﬁbers. Moreover, we
demonstrate that octanol, a GJ blocker, can prevent both the
functional and the morphological changes induced by oxaliplatin
ex vivo and in vitro.
2. Methods
2.1. Mouse strains and procedures
We used twomonth old wild type (WT) C57BL/6, as well as Gjb1-null mice/Cx32
knockout (KO) (C57BL/6_129) and Gjc3-null/Cx29 KO (129P2/OlaHsd*C57BL/6*SJL)
mice weighing 20e25 g, which were obtained from the European Mouse Mutant
Archive (Monterotondo, Italy), both originally generated by Prof. Klaus Willecke
(University of Bonn, Bonn, Germany). Animals were sacriﬁced using N2 and cervical
dislocation prior to nerve dissection. The sciatic nerve was exposed and dissected
from the spinal cord to the knee. All experimental procedures were conducted in
accordance with the animal care protocols outlined by the Aristotle University of
Thessaloniki, Greece and the Veterinary Authorities (License No 107241/2013) and
the Cyprus Government's Chief Veterinary Ofﬁcer according to EU guidelines (EC
Directive 86/609/EEC).
2.2. Ex vivo sciatic nerve recording bath
The sciatic nerves were immersed in a modiﬁed KrebseRinger solution con-
taining (in mmol/l): 136 NaCl, 4.7 KCl, 2.4 CaCl2, 1.1 MgCl2, 1 NaHCO3, 11 glucose, and
10 HEPES (all from Sigma, Germany); pH¼ 7.2. All experiments were performed at a
constant temperature of 25.0 ± 1.0 C. The epineural sheath was removed to ensure
that nerve ﬁbers came into direct contact with the drug under investigation and to
maximize drug access to all nerve ﬁbers. To expose the nerve to the drug under
investigation and simultaneously monitor its electrophysiological responses to
electrical stimuli (whole-nerve extracellular recordings), we used a three-
chambered recording bath made of parafﬁn as described in detail in our previous
studies (Kagiava et al., 2012). A similar, though slightly larger, recording bath, has
been used for a variety of neurotoxicological studies on the rat sciatic nerve (Kagiava
et al., 2008, 2013). Brieﬂy, the recording bath consists of three chambers: the
stimulating, the perfusion (middle), and the recording chamber. The chambers with
volume of 10e11 ml were placed in a row 1 mm apart. The nerve was mounted
across the three chambers of the recording bath with 2e3 mm of the proximal part
of the nerve placed in the stimulating chamber, where it was electrically stimulated
with supramaximal stimuli at 1 Hz (pulse amplitude: 2.0e3.0 V, duration: 0.01 ms)
using an electrode connected to a constant voltage stimulator (Digitimer, England,
UK) to evoke the CAP. Themain region of the nervee about 10e12mm, over 70.0% of
the total nerve length e was bathed in the perfusion chamber and was exposed to
the saline (control) or the drugs under investigation (oxaliplatin, octanol and their
combination). Finally, the distal part of the nerve was placed in the recording
chamber, where the evoked CAP was recorded using an electrode immersed in the
chamber connected to AC ampliﬁer (Neurolog NL822, Digitimer, UK). Immediately
after the placement of the nerve, each chamber was ﬁlled once with 10.0 ml
oxygenated (O2, 100%) saline. During the 24 h recording period the saline in the
perfusion chamber was continuously stirred using a miniature magnet and pH
remained stable. The electrodes (active and reference) from either ampliﬁer or
stimulator were made of 24-carat gold. Finally, the recording bath was air-tight
shielded to avoid evaporation of the saline during the long recording period (>20 h).
2.3. Electrophysiological data analysis
The amplitude of the CAP (example of baseline recorded evoked CAPs is given in
Fig. 1A) was measured from the baseline to the peak (in Volts). The duration of the
repolarizing phase of the CAP or the repolarizing time (RT) was measured from the
peak up to the end of the repolarizing phase (in ms), at the point where the repo-
larizing phase meets the baseline (example in Fig. 2A). CAP amplitude and RT
measured in Volts and ms, respectively, were expressed as a percentage of the initial
values at t¼ 0, or of the values before the application of the tested compound, which
were considered as 100%. Values obtained from repeated experiments were aver-
aged and expressed as means ± SEM. Using these values, the mean time-response
curves were plotted (example in Fig. 1E). Statistical signiﬁcance was examined by
one-way ANOVA and Student's t-test.
Fig. 1. The effects of octanol on mouse sciatic nerve isolated in the three-chamber
recording bath. (A) Recordings of the evoked CAP from a control nerve immersed in
normal saline. The time point of each CAP recording is indicated by (t). (BeD) show
representative recordings from nerves immersed in octanol 200 (B), 400 (C) and
600 nM (D). (E) Mean time-response curves (average of n ¼ 4e6 experiments) showing
the percentage decrease in the amplitude of the evoked CAP as a function of incubation
time in octanol 200, 400, 600 and 2000 nM, as indicated. The amplitude of the evoked
CAP at time 0, before the application of octanol, was considered to be 100%. The curve
marked with the open triangles represents the mean time-response curve for the
repolarising time (RT) of the evoked CAP obtained from nerves exposed to octanol
400 nM. The mean time-response curve for nerves exposed to normal saline is nearly
100% for 20 h (not shown for clarity). The bars represent ±SEM.
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The CAP of the mouse sciatic nerve immersed in normal saline solution remains
constant for over 24 h (Kagiava et al., 2012) indicating that the vitality of the sciatic
nerve ﬁbers under these recording conditions is not impaired. Oxaliplatin (Tocris
Bioscience) was pre-dissolved in distilled water to make the stock solution (5.0 mg/
ml) and stored under light protection at 20.0 C. Oxaliplatin from the stock was
diluted in the saline contained in the perfusion (middle) chamber to make the
desirable concentration, 25 mM, and single evoked CAPs were digitized and storedevery 5 min throughout the 1200 min (20 h) experiment, as described above. The
same procedure was followed to assess the effect of 200, 400, 600 and 2000 nM
octanol, 25 and 50 mM carbenoxolone, 25 and 50 mM, 18-beta-glycyrrhetinic acid
(GRA) and 100e300 mM octanoic acid (OA) (all from SigmaeAldrich). GRA and OA
were pre-dissolved in DMSO making stock solutions of 100 mM and then dissolved
in saline. To assess the action of the combination of oxaliplatin and octanol we used
three different conditions: a) octanol (400 nM) and oxaliplatin (25 mM)were applied
simultaneously and the preparation was left for 20 h with continuous CAP moni-
toring as above; b) the nerve was incubated ﬁrst in octanol (400 nM) for 40 min and
then 25 mM oxaliplatin was added in the perfusion chamber; and c) the nerve was
incubated ﬁrst in 25 mMoxaliplatin for 40min and then octanol (400 nM) was added
in the perfusion chamber. Carbenoxolone, GRA, and OA were applied only simul-
taneously with oxaliplatin as above.
2.5. Teased ﬁber preparation and immunostaining
Following the ex-vivo electrophysiological studies, sciatic nerves exposed for
either 3 or 24 h to oxaliplatin or to the combination of oxaliplatin plus octanol
(above) along with control nerves (stimulated for the same time but not exposed to
drugs), were ﬁxed for 30 min in fresh 4% paraformaldehyde (PFA) (Sigma, Germany)
in 0.1 M phosphate buffer (PB). Teased nerve ﬁbers were prepared from ﬁxed nerves,
dried on SuperFrost Plus glass slides overnight at room temperature and stored
at20 C. For immunostaining, teased ﬁbers were permeabilized in acetone (20 C
for 10 min) and incubated at room temperature with blocking solution (5% bovine
serum albumin (BSA), 0.5% Triton-X) for 1 h, followed by primary antibodies diluted
in blocking solution overnight at 4 C. Antibodies included mouse monoclonal
against Caspr (1:50; gift of Dr. Elior Peles, Weizmann Institute of Science), MBP
(1:500; Abcam), SMI31 (1:5000; Abcam), PanNav (1:50; Sigma), and Naþ/Kþ ATPase-
a1 subunit (1:100; Developmental Studies Hybridoma Bank, University of Iowa);
rabbit antisera against Cx29 (1:300; Invitrogen), MBP (1:100; Sigma), Kv1.2 (1:200;
Alomone), Caspr2 (1:100; Sigma), and Nav1.6 (1:100; Alomone), as well as goat-anti-
ATPase-a3 subunit (1:100; Santa Cruz). Teased ﬁbers were then washed in PBS and
incubated with appropriate ﬂuorescein- and rhodamine-conjugated donkey cross-
afﬁnity puriﬁed secondary antibodies (Jackson ImmunoResearch, 1:300) for 1 h at
room temperature. Schwann cell nuclei were visualized with 40 ,60-diamidino-2-
phenylindole (DAPI; SigmaeAldrich). Slides were mounted with Dako Fluorescent
Mounting Medium and images were photographed under a Zeiss ﬂuorescence mi-
croscope with a digital camera using the Zeiss Axiovision software (Carl Zeiss
MicroImaging, Germany). Where appropriate, we obtained images with comparable
exposure times to allow better comparison between different experiments.
2.6. Electron microscopy
Following ex-vivo electrophysiological studies, sciatic nerves exposed to oxali-
platin or to the combination of oxaliplatin plus octanol (above) along with control
nerves without pharmacological exposure, were ﬁxed in 2.5% glutaraldehyde in
0.1 M PB overnight at 4 C, then osmicated, dehydrated, and embedded in Araldite
resin. Transverse semi-thin sections (1 mm) were obtained and stained with alkaline
toluidine blue. Ultrathin sections (80e100 nm) were counterstained with lead cit-
rate and uranyl acetate before being examined in a JEOL JEM-1010 transmission
electron microscope (JEOL Ltd, Tokyo, Japan).
2.7. Neurobiotin uptake assay
Cx31.3-expressing clonal HeLa cells were generated by transfection using the
human Cx31.3 gene open reading frame (GenBank accession number AY297109)
cloned into pIRESpuro3 vector as previously described (Sargiannidou et al., 2008)
andmaintained in selection mediawith puromycin (0.5 mg/ml). Expression of Cx31.3
at the cell membrane of these cells was conﬁrmed by immunostaining and immu-
noblot analysis (Sargiannidou et al., 2008). For the neurobiotin uptake assay, cells
permanently expressing Cx31.3 were grown to about 50e70% conﬂuency in 4-well
chamber slides, washed in PBS lacking divalent ions, pre-incubated in Optimen for
30 min, and then incubated with 2% neurobiotin (Vector Laboratories, MW: 287, 1þ;
diluted in HBSS) for 5e60 min, washed and ﬁxed for 30 min in 4% PFA at 4 C. After
blocking in 5% BSA with 0.1% Triton X-100 for 30 min at RT, cells were incubated in
streptavidin-Texas red (Vector Laboratories,1:1000) at RT for 10min, counterstained
with DAPI and imaged as above. To determine the effects of oxaliplatin we per-
formed the same experiments in the presence of oxaliplatin alone (25 and 50 mM) or
oxaliplatin in combinationwith octanol (200 nMe2000 nM) diluted in Optimem for
30 min before and during incubation with neurobiotin.
For quantitative analysis of neurobiotin uptake with or without addition of
oxaliplatin and octanol in Cx31.3 expressing cells, the mean red channel pixel in-
tensity was measured in images captured with constant time exposures using the
ImageJ software (NIH image). At least 2000 cells in each condition were compared.
Statistical signiﬁcance was examined using the Student's t-test. All experiments
were performed in triplicates.
2.8. Neurobiotin scrape loading assay
Cx32 expressing clonal HeLa cells were plated on 6-well plates to reach
~90e100% conﬂuency on the day of the scrape loading. For neurobiotin scrape
Fig. 2. The neurotoxic effect of oxaliplatin and neuroprotective effect of octanol on the isolated mouse sciatic nerve: Representative recordings of the evoked CAP (time point of each
CAP recording is indicated by t) from nerves (A) incubated in 25 mM oxaliplatin; (B) incubated simultaneously in 400 nM octanol and 25 mM oxaliplatin; (C) incubated ﬁrst in 400 nM
octanol (ﬁrst arrow) and then 25 mM oxaliplatin was added (second arrow) in the perfusion chamber; (D) incubated in ﬁrst in 25 mM oxaliplatin (ﬁrst arrow) and then 400 nM
octanol was added (second arrow) in the perfusion chamber. (E) The mean time-response curves represent the percentage change in amplitude and RT (marked on the curves) of
the evoked CAP incubated in 25 mM oxaliplatin, as a fraction of incubation time (n ¼ 6). The amplitude of the evoked CAP at time 0, before the application of oxaliplatin, was
considered to be 100%. (F) as in (E) but the nerves were incubated in a mixture of 400 nM octanol and 25 mM oxaliplatin (n ¼ 5). (G) as in (E), but the nerves were either ﬁrst
incubated in 400 nM octanol for one hour and then 25 mM oxaliplatin was added (n ¼ 4; octanol before), or oxaliplatin was applied ﬁrst and then octanol added (n ¼ 3; octanol after,
only the plot of the initial CAP amplitude is shown). The bars represent ±SEM.
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neurobiotin was added alone, or in combination with either octanol 400 nM, oxa-
liplatin 25 mM, or with both octanol and oxaliplatin. A scalpel bladewas used to cut a
grid for scraping the cells, and then cells were incubated in neurobiotin for 15 or
30 min, washed 3 times in HBSS, ﬁxed with cold 4% paraformaldehyde (PFA) for
10 min, washed 3 times in PBS, blocked in 5% BSAwith 0.1% Triton X-100 for 30 min
at RT, incubated in streptavidin-rhodamine (Vector Laboratories, diluted 1:300) at
RT for 1 h, washed 3 times in PBS, 3 times in H2O, incubated with DAPI for 5 min at
RT, washed, dried, and pictures were taken as above. For quantiﬁcation of gap
junctional connectivity, the number of ﬂuorescent cells in a rectangle on one side of
the scrape line but excluding cells that were in the scrape line were counted and the
mean ± SEM were calculated for each condition and compared with the Student's
t-test.
3. Results
3.1. The effects of octanol on the sciatic nerve CAP
The evoked CAPs generated by 1 Hz supramaximal stimulation
of the mouse sciatic nerve representing the summation of action
potentials of all activated sciatic nerve ﬁbers (100% of myelinated
nerve ﬁbers) showed constant amplitudes over the 20e24 hrecording period (Fig. 1A), followed by a gradual decrease due to
nerve ﬁber inactivation, as in our previous studies (Kagiava et al.,
2012). Thus, the vitality of the sciatic nerve ﬁbers is not affected
by the recording conditions in the ﬁrst 1200 min (20 h) of the
experiment. Although nerve vitality lasts longer than 1200 min
(Fig. 1A), the incubation period with the compounds under inves-
tigation lasted for maximum of 1200 min. This was the period
where the probability to record CAPs of a constant amplitude and
duration was 100%. Beyond that time the CAP became unstable in
some experiments, therefore we assessed CAPs recorded only up to
1200 min exposure times to ensure reliability of the results.
In order to investigate the role of myelin GJs and hemichannels
in the generation of action potentials of the nerve ﬁbers and in
extend of the CAP, we ﬁrst examined the effects of the GJ blocker
octanol. Since previous studies suggested that octanol may inhibit
VGNaCs expressed in Xenopus oocytes with an IC50 of 72.1 ± 4.5 mM
within a range of 0.003 (min) e 3 mM (max) (Horishita and Harris,
2008), we used octanol concentrations of 200, 400, 600 and
2000 nM, far below the minimum concentration required to inhibit
VGNaCs. When the nervewas exposed to 200 nM octanol there was
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1200 min exposure (representative recordings in Fig. 1B and mean
timeeresponse curve from n ¼ 4 different experiments in Fig. 1E).
At a concentration of 400 nM octanol caused a nearly 50% decrease
of the initial value of the CAP almost immediately after application
(Fig. 1C, records t ¼ 10e60 min) followed by a gradual recovery
(records t ¼ 300e1200 min). The mean time-response curve
(400 nM in Fig. 1E) showed a CAP decrease to 46.5 ± 10.69% of its
original value (n ¼ 6) within 1 h, while by 6 h of exposure the CAP
recovered to 65.1 ± 10.97% and remained at this level despite
continuous exposure to octanol. Application of 600 nM octanol
caused a sharp decrease of the CAP amplitude to 42.3 ± 10.28%
within 1 h, gradually complete elimination of the CAPwithin 6e7 h,
and no recovery even after 20 h (600 nM in Fig. 1DeE; n ¼ 4).
Finally, application of 2000 nM octanol eliminated completely the
CAP amplitude within 1 h, without any recovery (2000 nM in
Fig. 1E; n ¼ 4). Thus, octanol caused a concentration-dependent
reversible decrease in CAP amplitude at 200 and 400 nM,
whereas a permanent elimination with loss of active nerve ﬁbers
occurred at 600e2000 nM, called here the “octanol-effect”. In
contrast to the inhibitory effect on CAP amplitude, exposure to
octanol had no effect on the duration of the CAP. For example, at
400 nM the duration of the CAP remained constant (duration curve
in Fig. 1E, open triangles).
3.2. Oxaliplatin prolongs the repolarization time (RT) of the sciatic
nerve CAP
Incubation of mouse sciatic nerve with oxaliplatin caused a
drastic, time-dependent, increase in the repolarizing time (RT) of
the CAP (Fig. 2A), similar to our previous ﬁndings in the rat sciatic
nerve (Kagiava et al., 2008, 2013). The effect started with a gradual
decrease of the negative part of the CAP repolarising phase (Fig. 2A,
records t ¼ 0 to t ¼ 40 min). The increase in RT, measured from the
peak of the CAP to the point where the repolarising phase meets
the baseline, started from 2.39 ± 0.08 ms under control conditions
and reached 26.2 ± 0.16 ms after 300 min of exposure (P < 0.01;
n ¼ 8 experiments) remaining at this level for 1200 min. Further-
more, in all eight experiments a second peak occurred on the main
CAP almost at the beginning of the exposure (Fig. 2A, t ¼ 60 min)
and persisted to the end of continuous recordings (t ¼ 1200 min).
The mean time-response curve with a per-minute sampling rate
showed that the RT increased up to 1173.8 ± 0.92% (n ¼ 8) of the
control values and remained at this level throughout the 1200 min
exposure to oxaliplatin (Fig. 2E, RT). This abrupt increase in the RT is
called here the oxaliplatin-effect. This broadening of the CAP
recorded extracellularly in the presence of oxaliplatin results from
broadening in the action potential of individual sciatic nerve ﬁbers,
as shown by previous intra-axonal recordings (Kagiava et al., 2013).
In contrast to RT, we found no signiﬁcant change in the CAP
amplitude at the initial (t ¼ 60 min) and at the ﬁnal stages
(t ¼ 1200 min) of the recording under 25 mM oxaliplatin exposure
(P > 0.05, n ¼ 8) (Fig. 2E). Importantly, the duration of the CAP
depolarizing phase reﬂected by the rise time of the CAP, during
which the VGNaCs are activated, remained unchanged.
3.3. Co-application of octanol and oxaliplatin abolishes the effects
of oxaliplatin
In order to test the possible protective role of the GJ inhibitor
octanol against OIN we exposed the sciatic nerve to 25 mM oxali-
platin and 400 nM octanol, both applied in the perfusion chamber
simultaneously. The 400 nM octanol concentration was chosen
because it had an intermediate inhibitory effect when applied alone
(Fig. 1C), without a drastic neurotoxic effect as seen with higherconcentrations (600 nM, Fig. 1D). This co-application had an effect
on both amplitude and RT of CAP. The CAP amplitude decreased
within the ﬁrst hour of exposure with gradual, almost full recovery
after 3e15 h (Fig. 2B), resembling the octanol-effect at 400 nM
(Fig. 1C and E). Interestingly, there was a much smaller increase in
the RTof the CAP, in contrast to themarked increase observedwhen
25 mM oxaliplatin was applied alone (Fig. 2A). During
co-application, the oxaliplatin-effect started with a loss of the
negative phase of CAP repolarization in the ﬁrst hour (Fig. 2B,
records t ¼ 0 to t ¼ 60 min), but at this point the oxaliplatin-effect
stopped, and there was no further increase in the RT, which
remained stable ranging from 2.33 to 3.92 ms (Fig. 2B, record
t¼ 120 to t¼ 1200min), indicating that octanol abolishes the effect
of oxaliplatin. The RT mean time-response curve (Fig. 2F), obtained
fromn¼ 5 experiments indicates that the octanol-effect dominated
over the oxaliplatin-effect. During co-application the effect of
octanol developed as a fast decrease of the CAP amplitude to
60.6 ± 8.08% of the control values within 1 h, followed by a rela-
tively slow recovery within 2e12 h. On the other hand, the
oxaliplatin-effect, the broadening of the CAP, was almost elimi-
nated and restricted drastically to an increase in the RT of the CAP
up to 146.0 ± 13.29% of the initial value (Fig. 2F), in contrast to the
>1173.75% increase in the presence of oxaliplatin alone (P < 0.05)
(Fig. 2E). This is a clear indication of neuroprotection of octanol
against oxaliplatin-induced neurotoxicity which reaches 88.6%.
Interestingly, oxaliplatin also provided mild “neuroprotection”
against the octanol-effect. While the maximum recovery of the CAP
amplitude when a nerve was exposed to 400 nM octanol only was
at the level of 64.0 ± 7.0% at 1200min (Fig.1E), co-administration of
octanol (400 nM) and oxaliplatin (25 mM) resulted in higher
recovery levels up to 98.2 ± 12.04% (P < 0.01) (Fig. 2F).
Addition of octanol 40 min prior to oxaliplatin incubation
resulted in weaker protection, while the octanol-effect, the
decrease and recovery of the CAP, persisted (Fig. 2C). The mean
time-response curve under these conditions (n ¼ 4 experiments)
showed an increase of the RT of CAP by 189.2 ± 4.28% in the ﬁrst
12 h of exposure and then further to 230.1 ± 13.65% (Fig. 2G),
signiﬁcantly higher compared to the corresponding experiment of
co-application (P < 0.05). Nevertheless, even with pre-application
octanol offered an 81.4% protection against OIN while the
octanol-effect (decrease and recovery of the CAP amplitude) fol-
lowed the same pattern as in the previous experiments (Fig. 2G). In
contrast, when oxaliplatin was added ﬁrst followed after 40 min by
octanol, the CAP was eliminated completely within less than
60 min, without any recovery after 1200 min, indicating that this
particular sequence was extremely toxic for the sciatic nerve ﬁbers
(Fig. 2D, G; n ¼ 4). Thus, only when octanol (400 nM) was applied
simultaneously or prior to oxaliplatin (25 mM) was there a signiﬁ-
cant protection against the oxaliplatin-effect on sciatic nerve ﬁber
function.
3.4. Concentration-dependent neuroprotection by octanol against
the oxaliplatin-effect
To investigate whether the neuroprotection was concentration-
dependent 200 and 600 nM octanol were also tested against the
oxaliplatin-effect. During co-application of 200 nM octanol plus
25 mM oxaliplatin there was a weaker neuroprotection with
increasing RTof the CAP followed byweak development of a second
peak of the waveform (Fig. 3A, record t ¼ 120e1200 min), which
never occurred in the previous treatment (400 nM octanolþ 25 mM
oxaliplatin). The mean time-response curves showed that the in-
crease in the RT reached amaximum of 172.3 ± 10.07%, signiﬁcantly
higher than with the 400 nM þ 25 mM combination (P < 0.05)
(Fig. 3C). Nevertheless, even at this low concentration (200 nM)
Fig. 3. Concentration-dependent neuroprotection of octanol against oxaliplatin-induced neurotoxicity in the mouse sciatic nerve: (A) Recordings of the evoked CAP from a nerve
immersed simultaneously in 200 nM octanol and 25 mM oxaliplatin. The time of exposure of the nerve to oxaliplatin for each CAP is indicated (t in min). (B) as in (A) but the nerve
was incubated in the mixture of 600 nM octanol and 25 mM oxaliplatin. (C) Mean time-response curves (RT and amplitude as indicated) obtained from 200 nM octanol/25 mM
oxaliplatin co-exposure (n ¼ 4) as in A. (D) Mean time-response curves obtained from 600 nM octanol/25 mM oxaliplatin co-exposure as in B (n ¼ 3). The amplitude and RT of the
evoked CAP at time 0, before the application of the mixture of octanol and oxaliplatin, was considered to be 100%. The bars represent ± SEM.
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close to the one at 400 nM (88.6%), while the octanol-effect was
milder with an amplitude decrease of 16% and a relatively slow
recovery (Fig. 3C).
The neurotoxic effect of 600 nM octanol, the elimination of the
CAP (Fig. 1E), was abolished in the presence of oxaliplatin. This
mixture minimized the amplitude of the CAP to 21.0 ± 10.03%
within 1 h (n ¼ 3) (Fig. 3B and D), as 600 nM octanol did when
applied alone (Fig. 1E), but within 3e5 h instead of eliminating the
amplitude of the CAP, there was a recovery up to 86.8 ± 7.80%
(Fig. 3B and D). Furthermore, during this unexpected inhibition-
recovery of the CAP by 600 nM octanol, octanol protected against
the oxaliplatin-effect, resulting in an increase of RT up to
144.5 ± 2.77% (n ¼ 3), far smaller compared to changes caused by
oxaliplatin alone (P < 0.05) (compare Fig. 3B, D and Fig. 2A, E). Thus,
even at a higher concentration of 600 nM octanol combined with
oxaliplatin (25 mM) resulted in a signiﬁcant (87.7%) neuroprotection
against the oxaliplatin-effect, offering overall a wider therapeutic
window with a concentration-dependent effect on nerve ﬁber
dysfunction.
3.5. Oxaliplatin-effect and neuroprotection by octanol are weaker
in Cx32 knockout nerves
Since octanol is considered to be a non-speciﬁc GJ blocker, there
are two known potential targets to mediate its protective effects
against oxaliplatin in myelinated nerve ﬁbers of the mouse sciatic
nerve: Cx32, which forms GJs through the layers of non-compact
myelin at paranodes and SchmidteLantermann incisures (Scherer
et al., 1995), and Cx29, which forms GJ hemichannels rather than
full GJs at the innermost myelin membrane apposing axonal jux-
taparanodes and juxtaincisures (Altevogt et al., 2002). In order to
distinguish the relevant connexin mediating the protective effects
of octanol, we performed the same experiments as above in ex vivosciatic nerves of Cx32 KO as well as Cx29 KO mice. In both Cx32 KO
and Cx29 KO nerves examined under control conditions (n ¼ 3
nerves per genotype) using the same recording bath, the CAP
generated by 1 Hz stimulation remained constant in amplitude and
duration for 1200 min. The recordings were identical to those ob-
tained from WT nerves (P > 0.05), indicating that the vitality and
physiological properties of sciatic nerves from either connexin KO
animals were not affected by the speciﬁc stimulating and recording
conditions (data not shown).
Application of 25 mMoxaliplatin on Cx32 KO nerves resulted in a
marked increase in the RT of the CAP (Fig. 4A), while the distinct
second peak observed in the recordings from the WT sciatic nerves
(Fig. 2A) was absent in all Cx32 KO nerves examined changing
signiﬁcantly the shape of the CAP waveform. The mean time-
response curve from n ¼ 9 Cx32 KO nerves (Fig. 4D) showed that
the RT broadening reached a maximum of 683.9 ± 36.5% (from
3.1 ± 0.25 to 22.7 ± 1.31 ms, P < 0.01) within 360 min, but then
decreased signiﬁcantly reaching a value of 430.3 ± 62.08% (P< 0.05)
near the end of the experiment (960e1080 min); these changes
were signiﬁcantly smaller compared to WT nerves, where RT was
prolonged by 1170.8 ± 1.86% at 360 min (P < 0.05) and remained
constant throughout the 1200 min experiment (Fig. 2E). Shorter RT
in the Cx32 KO CAP could be due to the absence of the second peak.
As in WT nerves the CAP amplitude was not signiﬁcantly affected
during treatment in Cx32 KO nerves (Fig. 4D). Thus, the oxaliplatin-
effect develops only partially in Cx32 KO nerves, showing some
similarities, but also important differences compared to nerves
from WT animals.
In order to examine whether octanol remains neuroprotective
against oxaliplatin also in Cx32 KO nerves, we ﬁrst clariﬁed the
effects of octanol alone. Application of 400 nM octanol caused the
same pattern of the inhibitory-recovery effect on CAP amplitude as
in WT nerves (Fig. 4B). However, the RT mean time-response curve
from Cx32 KO nerves showed a 30% (P < 0.05; n¼ 4) increase at the
Fig. 4. The effects of octanol, oxaliplatin and their mixture on the evoked CAP recorded from the isolated sciatic nerve of the Cx32 knockout (KO) mouse. Recordings of the CAP from
Cx32 KO nerves incubated in 25 mM oxaliplatin (A), in 400 nM octanol (B), or in a mixture of 400 nM octanol and 25 mM oxaliplatin (C). The time of recording of each CAP is indicated
(t in min). DeF: Diagrams showing the mean time-response curves of the CAP amplitude and RT recorded from Cx32 KO nerves during the exposure to 25 mM oxaliplatin (n ¼ 9) (D),
to 400 nM of octanol (n ¼ 4) (E), or to the mixture of 400 nM of octanol and 25 mM oxaliplatin (n ¼ 6) (F). The CAP amplitude and RT at time 0 before drug exposure was considered
to be 100%. The bars represent ± SEM.
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the experiment (Fig. 4E), in contrast to WT nerves which showed
almost constant RT (near 100%) when exposed to 400 nM of octa-
nol. Thus, the octanol-effect occurred also in Cx32 KO nerves but in
slightly different pattern compared to WT nerves.
Finally, co-application of 25 mM oxaliplatin plus 400 nM octanol
in Cx32 KO nerves protected against the broadening of the RT, the
oxaliplatin-effect (Fig. 4C). The mean time-response curve (Fig. 4F,
n ¼ 6) clearly indicated that the RT reached 193.5 ± 12.93% of the
initial value (P < 0.01 comparison to oxaliplatin alone) after treat-
ment for 360 min and then remained at this level for most of the
duration of the experiment, before showing a further increase to
237.2 ± 23.0% near the end of the experiment (t ¼ 1080 min).
However, the octanol neuroprotection against oxaliplatin-effect
was signiﬁcantly weaker in Cx32 KO nerves (71.7%) compared to
WT (88.6%) inwhich RT increased only to 146.0 ± 13.29% (P < 0.05).
Besides the neuroprotection of octanol against oxaliplatin in Cx32
KO nerves, therewas also an obvious protective action of oxaliplatin
against the octanol-effect, as also observed in WT nerves. In Cx32
KO nerves treated with 400 nM octanol the amplitude of the CAP
recovered only up to 83.7 ± 9.12% after 840 min (Fig. 4E), while in
nerves treated with octanol combined with oxaliplatin the
maximum recovery tended to be larger, 93.5 ± 11.06% (P > 0.05),
and appeared also at the same time as in the previous experiments,
after 840 min (Fig. 4F). In conclusion, the results in Cx32 KO nerves
indicate that the effects of oxaliplatin as well as the protective
action of octanol occurred but were signiﬁcantly weaker compared
to WT, implicating Cx32 GJ channels, at least in part, in OIN.
3.6. Oxaliplatin-effect and neuroprotection largely persist in Cx29
knockout nerves
Application of 25 mMoxaliplatin on Cx29 KO nerves resulted in a
marked increase in the RT of CAP (Fig. 5A). Also, in all Cx29 KO
nerves examined, the distinct second peak appeared as it was
observed in the recordings from the WT nerves (compare Figs. 2A
and 5A). The RT mean time-response curve from n ¼ 3 Cx29 KOnerves (Fig. 5C) showed that the RT was prolonged to a maximum
of 1035.0 ± 44.74% in 400e600 min and then declined to
441.3 ± 62.10% near the end of the experiment (1200 min). This
unusually fast increase and unstable reduction of RT, indicated by
large variations after 900 min (Fig. 5C) could be due to the gradual
decrease of CAP after 600 min of exposure to oxaliplatin (Fig. 5A
and C). Such drastic changes in these two parameters were not
observed in either WT or Cx32 nerves. Thus, the oxaliplatin-effect
develops also in Cx29 KO nerves showing important similarities
and minor differences compared to WT nerves.
Exposure of Cx29 KO nerves to the combination of oxaliplatin
(25 mM) and octanol (400 nM) showed a signiﬁcant (87.1%) neu-
roprotection, with a maximum RT increase of only 132.8 ± 4.92%
(Fig. 5D; n ¼ 3). Thus, the degree of neuroprotection offered by
octanol against the oxaliplatin effect in Cx29 KO nerves was not
different from WT nerves (88.6%; P > 0.05), whereas in was clearly
stronger than in Cx32 KO nerves (71.7%; P < 0.05). Taken together,
the ﬁndings from Cx32 KO and Cx29 KO nerves suggest that oxa-
liplatin affects the function of both Cx32 GJ channels and Cx29
hemichannels, but the effect on Cx32 appears to be more promi-
nent compared to Cx29.
3.7. Effects of other gap junction blockers against OIN
Based on the results of octanol we examined whether another
three GJ blockers, carbenoxolone, GRA and OA, could have a neu-
roprotective effect against OIN. We ﬁrst estimated the concentra-
tion with the minimum neurotoxicity on the sciatic nerve.
Carbenoxolone at 50 mM was found to be extremely neurotoxic
eliminating the CAP in 120e300 min (n¼ 4), while at 10 and 25 mM
(n ¼ 4 each) carbenoxolone had a milder effect causing a 20%
decrease at the beginning of exposure and then a recovery within
1200 min (Fig. 6A). However, at this non-toxic concentration of
25 mM, carbenoxolone failed to provide neuroprotection against the
oxaliplatin-effect when tested in simultaneous administrationwith
25 mM oxaliplatin (n ¼ 4) (Fig. 6D), since RT increased up to
1107.1 ± 36.79%.
Fig. 5. The effects of octanol, oxaliplatin and their mixture on the evoked CAP recorded from the isolated sciatic nerve of the Cx29 KO mouse. Recordings of the CAP from Cx29 KO
nerves incubated in 25 mM oxaliplatin (A) and in a mixture of 400 nM octanol and 25 mM oxaliplatin (B). The time of recording of each CAP is indicated (t in min). CeD: Diagrams
showing the mean time-response curves of the CAP amplitude and RT recorded from Cx32 KO nerves during the exposure to 25 mM oxaliplatin (n ¼ 3) (C), or during exposure to the
mixture of 400 nM of octanol and 25 mM oxaliplatin (n ¼ 3) (D). The CAP amplitude and RT at time 0 before drug exposure was considered to be 100%. The bars represent ± SEM.
Fig. 6. AeC: Concentration-dependent effects of carbenoxolone (CBX), 18-beta-glycyrrhetinic acid (GRA) and octanoic acid (OA) on the mouse sciatic nerve. CBX is toxic at 50 mМ
rapidly reducing CAP amplitude, while it is only minimally toxic up to 25 mМ (A). GRA also shows toxicity at 50 mM and to a lesser degree at 25 mМ, that develops more gradually (B).
OA starts having mild toxic effects at 300 mМ (C). When co-administered with 25 mМ oxaliplatin, carbenoxolone fails to show any protective effect at a non-toxic concentration (D),
while GRA at 25 mМ shows signiﬁcant neuroprotection ameliorating RT prolongation by 78.8% (E), and OA at 300 mМ shows a modest protection of 37.6% (F).
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toxic, decreasing the CAP amplitude to 25% of the control within
720 min (Fig. 6B), while 25 mM of GRA proved to be less toxic
maintaining the CAP amplitude near 50% of its original value (Fig. 6
B). Co-application of 25 mMGRA and 25 mM of oxaliplatin showed asigniﬁcant neuroprotection since the RT increased only up to
248.5 ± 38.39% (Fig. 6E), instead of 1173.8 ± 0.92% when oxaliplatin
was applied alone (78.8% neuroprotection, P < 0.01). Furthermore,
as already shownwith octanol (above), we observed a protection of
oxaliplatin against the inhibitory effect of GRA on the CAP
A. Kagiava et al. / Neuropharmacology 97 (2015) 289e305 297amplitude. 25 mM GRA alone decreased the CAP to 50% (Fig. 6B),
while in the presence of oxaliplatin only to 75% of baseline
(P < 0.05). Thus, GRA provides a similar neuroprotection against
OIN as seen with octanol, although with a smaller therapeutic
window.
Finally, three concentrations, 100, 200 and 300 mM of OA were
tested (n ¼ 3 each). The ﬁrst two had only a minor effect on the
vitality of nerve ﬁbers, since the CAP remained at the same level
throughout the exposure (1200 min) (Fig. 6C), while the concen-
tration of 300 mM caused a decrease of the CAP to 65.6 ± 7.17%
(Fig. 6C). Co-application of the high concentration of 300 mM with
25 mM oxaliplatin had only a mild protective effect (37.6% protec-
tion), since the increase of RT reached 731.6 ± 53.24%, compared to
1173.8 ± 0.92% when oxaliplatin was applied alone (P < 0.05).
3.8. Morphological changes caused by the prolonged exposure to
oxaliplatin
In order to examine whether there is a morphological correlate
to the functional changes caused by oxaliplatin in peripheral nerve
ﬁbers described above, we also immunostained teased ﬁbers from
sciatic nerves following the 20 h ex vivo study. Most ﬁbers were
well preserved and were double stained with myelin and axonal
markers, as well as markers of axonal domains including Nav1.6/
PanNav at nodes, Kv1.1 or Caspr2 at juxtapanodes and Caspr atFig. 7. Juxtaparanodal abnormalities in myelinated ﬁbers after prolonged oxaliplatin expos
exposed to normal saline (A, D, G, J, M) and nerves exposed to 25 mM oxaliplatin alone (B, E
recording bath under continuous 1 Hz stimulation for over 24 h. Both merged images and i
axonal marker SMI31 (green) and myelin basic protein (red) in AeC, with Cx29 (red) combin
Nav1.6 (red) combined with Caspr (green) (JeL), as well as for Naþ/Kþ ATPase a1 subunit
arrowheads) (MeO), as indicated. In control ﬁbers nodes are surrounded by paranodal mye
widening of SMI31 immunoreactivity at paranodal and juxtaparanodal areas (arrows) and t
abnormality is not seen in ﬁbers treated with oxaliplatin plus octanol. Double labeling with C
ﬁbers exposed to oxaliplatin (E), although the organization of axonal domains and localizatparanodes, in combination with Cx29. Fibers from sciatic nerves
exposed to oxaliplatin for 20 h frequently showed a characteristic
enlargement of juxtaparanodal axonal areas, which appeared to
cause a thinning of the surrounding myelin and retraction away
from paranodal areas (Fig. 7B, E). The characteristic myelin loops
surrounding the paranodes that are seen in control ﬁbers were
thinner or not visible. However, the localization of Cx29, Kv1.1,
Caspr2, Caspr and Nav was not disturbed, indicating that axonal
domains were preserved (Fig. 7DeL). Naþ/Kþ ATPase a1 subunit
along the axon and a3 subunit in non-compact myelin areas were
also preserved (Fig. 7MeO). Juxtaparanodal swelling was not seen
in ﬁbers treated with the combination of oxaliplatin and octanol or
in untreated ﬁbers that were also stimulated for 20 h with same
frequency (Fig. 7A, C). Thesemorphological changeswere not found
in nerves examined after a short exposure to oxaliplatin for 3 h
(data no shown), despite signiﬁcant broadening in the repolarizing
phase of the evoked CAP at this time point (Fig. 2A), suggesting that
functional changes are initially not accompanied by morphological
changes, and that juxtaparanodal swelling occurs only with longer
oxaliplatin exposure.
To further clarify the nature of the morphological changes
observed by immunostaining, we also examined semithin and ul-
trathin sections of ex vivo stimulated nerves exposed to each con-
dition and control nerves. In semithin sections of nerves exposed to
oxaliplatin, we observed a widening of axonal diameter ature ex vivo. Images of sciatic nerve teased ﬁbers obtained from control sciatic nerves
, H, K, N) or combined with 400 nM octanol (C, F, I, L, O). All nerves were placed in the
nsets with separate channels underneath are shown. Fibers were immunostained with
ed with juxtaparanodal Kv1.1 (DeF) or with paranodal Caspr (G-I) (green), with nodal
along the axon (red open arrowheads) and a3 subunit at the incisures (green open
lin forming loops around the axon, whereas in ﬁbers exposed to oxaliplatin there is a
he surrounding myelin sheath is thinner and appears retracted away from nodes. This
x29 and Kv1.1 or Caspr and Nav1.6 with Caspr shows the widening of juxtaparanodes in
ion of Nav1.6 and Kv1.1 channels and ATPase subunits is not altered. Scale bar: 10 mm.
Fig. 8. Ultrastructural changes in sciatic nerve myelinated ﬁbers after prolonged exposure to oxaliplatin and prevention by octanol. AeC: Images of longitudinal semithin sections
from ex vivo stimulated sciatic nerves treated with oxaliplatin alone (B) or in combination with octanol (C) or control treated with saline (A). Nodal areas are indicated (arrows),
demonstrating in the control nerve the normal architecture of the perinodal areas (open arrowheads), with myelin sheath forming paranodal loops. In contrast, the oxaliplatin
treated nerve shows widening of the paranodal and juxtaparanodal area of the axon, causing an obliteration of the paranodal myelin loops, thinning and retraction of the myelin
away from the node. Images of ultrathin sections (DeL) conﬁrm the widening of paranodal areas showing a homogeneous axonal area with reduced density consistent with edema
and lack of any inclusions in oxaliplatin treated ﬁbers (E, HeL), while nodal structures are preserved (E, K). This axonal swelling is associated with thinning and ﬂattening of
perinodal myelin, obliteration of septate junctions and retraction of myelin from paranodal areas (arrowheads). Normal axonal domains, septate junctions, paranodal myelin loops
(stars) and normal juxtaparanodal myelin thickness can be seen in the control ﬁbers (D) and in oxaliplatin plus octanol treated ﬁbers (F). Similar axonal swelling and thinning of the
myelin sheath in oxaliplatin treated nerves can be seen in axonal areas surrounded by SchmidteLantermann incisures (H), as opposed to the normal appearance of juxta-incisures in
control nerves (G). Scale bars: in AeC 10 mm; in DeL: 2 mm.
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(Fig. 8B). These changes were not observed in control nerves or in
nerves treated with the combination of oxaliplatin and octanol
(Fig. 8A, C). Further examination of these axonal changes by elec-
tron microscopy showed that swollen perinodal areas were
edematous, and did not contain any dense or aggregated material.
In addition, the axonal cytoskeletal elements such as microtubules,
neuroﬁlaments and associated mitochondria, which are normally
dense in perinodal areas, were rareﬁed. The septate axon-glial
paranodal junctions were obliterated and the surrounding myelin
sheath appeared retracted and thinner over the edematous
paranodal and juxtaparanodal axonal areas. Nodal structures were
clearly preserved in most swollen axons (Fig. 8E, IeL). Similar
edematous axonal swellings were observed in axonal areas
surrounded by SchmidteLantermann incisures (Fig. 8H). Thus,
prolonged (20 h) exposure to oxaliplatin causes profound
morphological changes in axons, in addition to the functional
changes that occur within the 3 h of oxaliplatin exposure and are
initially not accompanied by any morphological changes.
3.9. Oxaliplatin causes increased opening of Cx31.3 hemichannels
and Cx32 GJ channels in vitro
Our electrophysiological experiments indicated that oxali-
platin effects on the peripheral nerve may be mediated in part
through Cx29 hemichannels localized at the inner myelinmembrane in close apposition to axonal VGKCs. To further
investigate this possibility, we studied the effects of oxaliplatin
on clonal HeLa cells expressing the human ortholog of Cx29,
Cx31.3, which have been shown to form functional hemichannels
on the cell surface (Sargiannidou et al., 2008). Cx31.3 hemi-
channel function was assessed by the neurobiotin uptake assay.
Cx31.3 expressing cells were incubated with or without the
addition of oxaliplatin (25 and 50 mM concentrations). Neuro-
biotin uptake increased over time reaching a plateau after one
hour in unexposed Cx31.3 cells (Fig. 9D), while in the presence of
oxaliplatin, neurobiotin uptake was accelerated, reaching a
plateau already after 20 min of exposure, and was signiﬁcantly
increased at all time points examined (P < 0.05) (Fig. 9E) indi-
cating forced opening of Cx31.3 hemichannels. These results
were conﬁrmed by quantitative analysis in at least 3 independent
experiments with counts of neurobiotin signal intensity in at
least 2000 cells per time point (Fig. 9G). This effect of oxaliplatin
on neurobiotin uptake was blocked by octanol (200e1000 nM) in
a dose-depended manner (P < 0.05) (examples in Fig. 9F and
quantiﬁcation from 3 independent experiments in H), conﬁrming
that it is mediated through opening of Cx31.3 hemichannels.
Thus, oxaliplatin appears to open GJ hemichannels, an effect that
can be blocked by octanol. Furthermore, oxaliplatin has similar
effects on Cx31.3, the human ortholog of rodent Cx29, assessed in
clonal cells, supporting the relevance of this effect for OIN in
humans.
Fig. 9. Oxaliplatin accelerates Cx31.3 hemichannel opening and this effect is blocked by octanol in a dose-dependent manner. Expression of Cx31.3 in clonal Hela cells on the cell
surface was conﬁrmed by immunostaining with speciﬁc anti-Cx31.3 antibody (A), in contrast to control HeLa cells showing no speciﬁc Cx31.3 immunoreactivity (B). Representative
images of Cx31.3-expressing cells from different neurobiotin incubation times as indicated without (D) or with oxaliplatin preincubation (E) shows increased neurobiotin signal at
all time points in oxaliplatin treated cells. Cx31.3 cells without neurobiotin incubation show no speciﬁc signal (C). Quantiﬁcation from 3 independent experiments (G) shows
signiﬁcantly higher neurobiotin uptake at all time points in oxaliplatin treated cells. Accelerated uptake in the presence of oxaliplatin is most pronounced at earlier intervals and
reaches a plateau within 20 min, while in the absence of oxaliplatin the plateau is reached after 60 min. F: Exposure of Cx31.3 cells to combination of oxaliplatin and increasing
concentrations of octanol for 20 min shows that the effect of oxaliplatin is blocked by octanol in a dose-depended manner. Quantiﬁcation of neurobiotin signal (H) conﬁrms the
signiﬁcant antagonism of the oxaliplatin effect by increasing octanol concentrations. *: P < 0.05; **: P < 0.01; ***: P < 0.001.
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channels formed by Cx32 in myelinated ﬁbers, we also examined
in vitro the effect of oxaliplatin in cultured cells expressing the
human Cx32. In order to assess Cx32 GJ channel function, we used
the neurobiotin scrape loading assay. The addition of 25 mM oxa-
liplatin resulted in accelerated dye coupling between cells after
15 min compared to baseline dye coupling (p < 0.05). This effect of
oxaliplatin was blocked by co-administration of octanol 400 nM
(Supplementary Fig. 1). Thus, oxaliplatin appears to also cause
opening of Cx32 GJ channels.
4. Discussion
Peripheral neuropathy remains the main dose-limiting toxicity
of oxaliplatin in the majority of treated patients (Kweekel et al.,
2005; Park et al., 2009). The clariﬁcation of the cellular mecha-
nisms underlying OIN in the peripheral nervous system and iden-
tiﬁcation of a successful neuroprotective strategy could have a
major impact on improving patient quality of life and the ability to
deliver full doses of oxaliplatin. Using the ex vivo preparation based
on the isolated sciatic nerve of the mouse, we ﬁrst examined
separately the functional effects of octanol, a GJ blocker, and oxa-
liplatin on the sciatic nerve ﬁbers and then in co-application. Our
work was combined with morphological and in vitro studies, to
demonstrate the neuroprotective properties of octanol. Our study
implicates both Cx32 GJ channels and Cx29/Cx31.3 hemichannels in
OIN and demonstrates that the co-administration of the GJ blocker
octanol can prevent the effects of oxaliplatin on peripheral nerve
myelinated ﬁbers. Octanol appears to offer the best therapeutic
window compared to three other GJ blockers tested, which showed
weaker neuroprotective effects and more toxicity. Furthermore, we
provide an explanation for the origin of hyperexcitability in acute
OIN, as well as a structural correlate for the chronic manifestations.
The main advantage of our study is the use of the ex vivo
preparation of the isolated mouse sciatic nerve, which provides
stable in amplitude and duration recordings from either WT, Cx32
KO and Cx29 KO animals for at least 20 h. The long vitality of all
three types of nerves in saline allowed us to perform long-term
neuropharmacological experiments using a relatively low concen-
tration of either octanol 200e600 nM, or oxaliplatin 25 mM. The
concentration of oxaliplatin used in this study was only slightly
above the concentrations used in clinical practice where after a
dose of 130 mg/m2 infused over 2 h, the plasma platinum mean
Cmax values were in the range of 2.59e3.22 mg/ml corresponding to
6.5e8.11 mM (Graham et al., 2000) or 3e6 mg/ml (8e16 mM) (Eckel
et al., 2002). Moreover, the same oxaliplatin-effect was demon-
strated in our previous ex vivo experiments evenwith amuch lower
concentration of 5 mM (Kagiava et al., 2008), but with a delay of
15e20 h. Therefore, we used here the concentration of 25 mM in
order to provide clinical relevance to our ex vivo experiments (Kern
et al., 1999), but also to have the oxaliplatin-effect developedwithin
the time frame when the nerve preparation is still in perfect
functional condition. In contrast, previous studies using similar
nerve exposure models applied oxaliplatin 75e500 mM in order to
achieve effects within 10e20 min (Adelsberger et al., 2000;
Grolleau et al., 2001; Webster et al., 2005; Scuteri et al., 2010), an
unusually high concentration which could have multiple effects on
myelinated nerve ﬁbers that may not be clinically relevant.
4.1. The effects of octanol on sciatic nerve GJs and GJ hemichannels
Octanol is a well-known GJ and GJ hemichannel blocker
(Verselis and Srinivas, 2013), but has also been reported at higher
concentrations to act as a blocker of Nav channels with an IC50 of
75 mM (Horishita and Harris, 2008) or even 455 mM (Poyraz et al.,2003). Here, octanol was tested against GJ and GJ hemichannels
of myelinated nerve ﬁbers at a much lower concentration of 200
and 400 nM causing an inhibition-recovery effect on the CAP
amplitude, the octanol-effect, while at higher concentration over
600 nM it became neurotoxic, eliminating completely the ampli-
tude of the CAP within 1 h at 2000 nM. The rapid decrease of the
CAP amplitude indicates a fast loss of active nerve ﬁbers. Interest-
ingly, the strong inhibition of the CAP amplitude by octanol at such
low concentrations conﬁrms that GJs and GJ hemichannels located
on the myelin sheath play a signiﬁcant role in the generation and
propagation of the action potential. These effects of octanol indicate
that Cx29 and Cx32 play the main role in the homeostasis of Kþ in
the periaxonal space at juxtaparanodes and juxtaincisures. The
possible action of octanol against VGNaCs has already been
excluded.
Cx29 hemichannels are located in the juxtaparanodal region in
close proximity to the VGKCs and they provide a direct communi-
cation pathway between the periaxonal juxtaparanodal space and
the Schwann cell, suggesting a close functional relationship
(Altevogt et al., 2002). On the other hand, Cx32 forms GJs through
the layers of non-compact myelin at paranodal loops and
SchmidteLantermann incisures (Scherer et al., 1995) and plays an
even more important role in the homeostasis of myelinated ﬁbers
and for preserving homeostasis in the periaxonal space (Anzini
et al., 1997; Balice-Gordon et al., 1998; Sargiannidou et al., 2009;
Vavlitou et al., 2010; Kleopa, 2011). Cx32 is required for normal
function in peripheral nerves, as also demonstrated by the pro-
gressive neuropathy occurring in Cx32 KO mice (Anzini et al., 1997;
Scherer et al., 1998; Sargiannidou et al., 2009; Vavlitou et al., 2010),
as well as by the human disorders associated with Cx32 dysfunc-
tion (Kleopa, 2011). In contrast, Cx29 appears to play a less
important role, since Cx29 KOmice show nomorphological or basic
electrophysiological abnormalities in the PNS or CNS (Eiberger
et al., 2006) except for auditory neuropathy in 50% of cases (Tang
et al., 2006).
4.2. The role of myelin GJ channels and hemichannels in Kþ spatial
buffering
GJs and GJ hemichannels appear to play a crucial role in extra-
cellular Kþ buffering at juxtaparanodes and periaxonal space, since
blocking by octanol at 600e2000 nM in this study caused cancel-
lation of the action potentials and eventually the loss of CAP, likely
resulting from excess Kþ in the periaxonal space causing the mal-
function of VGKCs. Others have similarly shown that the extra Kþ
can modify membrane excitability (Kume-Kick et al., 2002) and
even lead to hyperexcitation of myelinated nerve ﬁbers (Chiu, 1991;
Lev-Ram and Ellisman, 1995). Rapid clearance of Kþ from the jux-
taparanodal periaxonal space is essential because during repetitive
action potentials Kþ released by VGKCs in this very narrow space
may reach concentrations of over 60 mM due to a very small dis-
tribution volume (Astion et al., 1988).
Based on our results of octanol interaction with GJ and GJ
hemichannels and the known location and functional role of VGKCs
in myelinated ﬁbers (Konishi, 1990; Chiu, 1991), we propose the
following siphoning mechanism by which GJ and GJ hemichannels
may regulate the outﬂow of excess Kþ from the juxtaparanodal
region, which is also in keeping with previous studies (Altevogt
et al., 2002; Menichella et al., 2006): during an action potential
the depolarization caused by the nodal Naþ current activates both
axonal Kv1.1/Kv1.2 and apposing GJ hemichannels so that they
open almost simultaneously, or with a minor delay, the GJ hemi-
channels preceding the VGKCs. Almost all types of GJ hemichannels
are activated (open) upon axon depolarization and are effectively
closed by hyperpolarization (Paul et al., 1991; Valiunas and
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substantial cation ﬂuxes (Trexler et al., 1996). During this syn-
chronized opening Kv1.1/Kv1.2 deliver Kþ into the narrow juxta-
paranodal periaxonal space, Cx29 GJ hemichannels transfer the
excess Kþ into the adaxonal Schwann cell cytoplasm, and from
there it is further transported through the radial pathway formed
by Cx32 GJs to the abaxonal Schwann cell cytoplasm. This ﬂow
results from accumulation of Kþ charging positively the juxtapar-
anodal periaxonal space combined with the negative Schwann cell
membrane potential, near40 mV (Hargittai et al., 1991). This brief
inﬂux of Kþ into the Schwann cell through the open hemichannels
and GJ channels following electrical gradients lasts for a few mil-
liseconds and stops at the end of action potential. Cx29 GJ hemi-
channels are the only known channels apposing juxtaparanodal
axonal VGKCs (Altevogt et al., 2002), whereas Cx32 GJs are
concentrated in the surrounding non-compact myelin areas
(Scherer et al., 1995; Kleopa, 2011). Other channel types such as
Kir2.1 and Kir2.3 are located at the microvilli surrounding the
nodes of Ranvier (Mi et al., 1996) and may buffer extracellular Kþ at
the node, while Schwann cells may transport excess Kþ from the
cytoplasm to the capillaries through other channels facing the
basilar membrane, including Kv1.5 (Horio, 2001).
4.3. The oxaliplatin effect
The functional correlate of OIN in the sciatic nerve ﬁbers of the
mouse, as demonstrated here, consists of a characteristic severe,
time and concentration-dependent broadening of the evoked CAP
repolarising phase, an effect also observed in other similar ex vivo
studies (Adelsberger et al., 2000; Grolleau et al., 2001; Webster
et al., 2005; Kagiava et al., 2008, 2013). This broadening results
from increased duration of the RT (by about 300e400% of control)
demonstrated in the intra-axonally recorded evoked action po-
tentials from rat nerve ﬁbers exposed to oxaliplatin (Kagiava et al.,
2013). This type of prolongation indicates a hyperexcitation of the
nerve ﬁbers but only during the evoked action potential, since their
resting membrane potential remains constant, between 80
and 90 mV, for over 1 h incubation in oxaliplatin (Kagiava et al.,
2013). Our previous work (Kagiava et al., 2008) has shown that
this unusual hyperexcitation caused by oxaliplatin in rat nerve
ﬁbers is closely related to the malfunction of VGKCs (Vabnick et al.,
1999; Rasband et al., 2002). Interestingly, peripheral nerve ﬁber
hyperexcitability that develops acutely following oxaliplatin
exposure resembles neuromyotonia, a channelopathy linked to
dysfunction of juxtaparanodal VGKCs (Hart et al., 2002; Kleopa
et al., 2006; Van Poucke et al., 2012). Furthermore, the effects
blocking VGKCs with 4-AP in nerve ﬁbers from young animals
before completed myelination (Astion et al., 1988) had a striking
similarity with the recordings obtained after oxaliplatin treatment
in adult nerve ﬁbers (Kagiava et al., 2013), a clear indication of
VGKCs malfunction during this unusual hyperexcitability devel-
oping only during the action potential. However, in contrast to
4-AP, direct binding of oxaliplatin to juxtaparanodal Kv1.1/1.2
VGKCs could not be conﬁrmed (Adelsberger et al., 2000; Broomand
et al., 2009) suggesting that VGKC involvement in OIN is likely
through a functionally related target.
The severe broadening of RT of the evoked CAP by 25 mM oxa-
liplatin, found in all nerves examined, could be interpreted as a
direct distortion of VGKCs, causing increase of Kþ in the ﬁber.
However, this is not the case since the whole oxaliplatin-effect was
reversed by 88.6% though octanol, a well-known blocker of GJ
channels and hemichannels. This a clear indication that the mal-
function of VGKCs during the oxaliplatin-effect is secondary to
dysfunction of GJ and GJ hemichannels Thus, the conclusion is that
oxaliplatin acts as an opener of GJ channels and hemichannels,causing a state of prolonged opening as also reported in other
pathological conditions (Contreras et al., 2003; Gomes et al., 2005;
Retamal et al., 2007; Orellana et al., 2010).
In order to clarify whether octanol acts on full GJs formed by
Cx32 (Scherer et al., 1995) or on GJ hemichannels formed by Cx29
(Altevogt et al., 2002), the only known connexin channels in pe-
ripheral nerves, or both, we further investigated its effects in Cx32
KO and Cx29 KO mice. The vitality of the KO nerves was not
signiﬁcantly affected by the recording conditions although Cx32
and Cx29 are important for myelinated nerve ﬁber function
(Altevogt et al., 2002; Scherer et al., 1995). This is probably due to
low frequency stimulation (1 Hz), which allows the remaining GJs
or GJ hemichannels to maintain adequate homeostasis. KO nerves
also responded to 400 nM octanol as the WT nerves. A difference
was seen in the response to oxaliplatin, which was almost identical
for Cx29 KO and WT (RT>1035%), but lower (683.9%) for the Cx32
KO. Shorter RT in the Cx32 KO CAP could be due to the absence of
the second peak of the CAP waveform, observed in both WT and
Cx29. Also, there was a signiﬁcant difference in the response to
prolonged exposure to oxaliplatin, during which in WT nerves RT
increase persisted for over 1200 min while in the KO nerves there
was a peak near 240e340 min and then the RT gradually
decreased. Finally, the protection by octanol against the
oxaliplatin-effect persisted in both connexin KO nerves, although
with lower intensity in Cx32 KO than in Cx29 KO. Taken together,
these results support our conclusion that oxaliplatin acts as an
opener of GJ channels more than hemichannels in peripheral nerve
ﬁbers.
Prolonged or even permanent GJ channel and hemichannel
opening in the presence of oxaliplatin would ﬁrst prevent the
removal of the excess Kþ caused by the activation of VGKCs and
then permit passive, non-physiological Kþ transport from the
Schwann cell cytoplasm to the juxtaparanodal periaxonal space
following concentration gradients, gradually building a surplus of
Kþ in this region. Disruption of Kþ homoeostasis by oxaliplatinwith
increased extracellular Kþ in the juxtaparanodal region is expected
to affect VGKC function, explaining the increase of 400% in the
repolarising phase of the action potential (Kagiava et al., 2013) and
eventually the increase in the RT of the CAP shown here. The axon
responds to this excess of extracellular Kþ by post-stimulus re-
petitive ﬁring, which increases in frequency with time of exposure
to oxaliplatin (Kagiava et al., 2013). This repetitive ﬁring starts
when repolarizing of the action potential reaches values near 48
to 50 mV, the activation level of the fast Kv channels (Baker and
Ritchie, 1996), and ends near the normal resting membrane po-
tential of 90 mV (Kagiava et al., 2013). This has been suggested to
act as a pumping mechanism for the release of the excess Kþ from
the axon to the periaxonal juxtaparanodal region (Kagiava et al.,
2013). Such a repetitive ﬁring has also been observed in rat nerve
ﬁbers exposed to 4-AP (Astion et al., 1988) or even in the CNS of the
locust, where pharmacological blockade of GJs induces repetitive
surging of extracellular Kþ. Thus, glial spatial buffering through GJs
plays an essential role in the regulation of [Kþ] under normal
conditions, contributing to Kþ clearance following physiologically
elevated levels (Rash, 2010; Spong and Robertson, 2013). These
phenomena are clinically relevant, as in oxaliplatin treated patients
nerve conduction studies reveal hyperexcitability which appears as
repetitive motor discharges after single electrical stimulus (Wilson
et al., 2002; Lehky et al., 2004), while sensory hyperexcitability
ﬁndings precede the development of neuropathy (Park et al., 2009).
Why cold induces paresthesias in acute OIN (Lehky et al., 2004)
remains unclear, but this phenomenon may be related to the fact
that cold impairs GJ conductance as well as biosynthesis
(Bukauskas and Weingart, 1993; Saitongdee et al., 2000), so that GJ
channels may be more vulnerable to the effects of oxaliplatin at
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to clarify the role of temperature in OIN.
4.4. Neuroprotection of octanol against oxaliplatin
Octanol when applied simultaneously with oxaliplatin
compensated for the opening of GJ channels and hemichannels by
oxaliplatin rescuing the prolongation of the CAP repolarising time
from 1173.8 ± 0.92% of baseline when oxaliplatin was applied alone
to only 146.0 ± 13.29% even after 1200 min incubation, an 88.6%
protection. Indeed, the neuroprotection offered by octanol was
slightly concentration-dependent with a minimum at 200 nM
(85.3% protection of RT prolongation) and a maximum at 600 nM
(87.7% protection). Octanol offers almost the same neuroprotection
at the low concentration of 200 nM as at the higher and neurotoxic
600 nM. This is clinically relevant because the minimum effective
octanol concentration should be used, tominimize the side effect of
decreasing the CAP amplitude and the number of malfunctioning
nerve ﬁbers. Furthermore, supporting its opposite action of GJ
channels and hemichannel opening, oxaliplatin appeared to protect
against the octanol-effect, the inhibition-recovery of CAP ampli-
tude. In the presence of oxaliplatin and 400 nM octanol there was a
98% maximum recovery in the amplitude of CAP, instead of 67%
when octanol was applied alone. The protective role of oxaliplatin
became even more pronounced when applied simultaneously with
600 nM octanol, a concentration that proved to be neurotoxic for
the nerve ﬁbers when applied alone. With this combination the
CAP recovered up to 90%, as opposed to complete loss in the
presence of 600 nM octanol alone. This is a clear indication that the
opening and ﬁxation of GJ and GJ hemichannels by oxaliplatin is
compensated by octanol.
These mutual neuroprotective effects occurred only when the
two compounds were added simultaneously or when the nerve
was pre-incubated in octanol. In contrast, when the nerve was pre-
incubated in oxaliplatin and then in octanol the neuroprotective
effect became neurotoxic. The reason for this phenomenon remains
unclear, but may be related to the nature of interaction of each
compound with the connexins channels, that could involve com-
mon or different binding sites and cause conformational changes of
channel forming domains (Spray et al., 1986) affecting the subse-
quent binding of the other compound. Octanol, similar to other GJ
blockers, has been shown to bind only to extracellular connexin
sites that differ from the Ca2þ binding site (Eskandari et al., 2002),
while the biophysical interaction of oxaliplatin with connexins will
need to be clariﬁed in future studies. A similar effect was reported
in other models where connexin hemichannel blockade was neu-
roprotective after, but not during global cerebral ischemia in near-
term fetal sheep (Davidson et al., 2014). The neuroprotective role of
octanol against oxaliplatin found in the sciatic nerve preparation
was veriﬁed by our in vitro experiments in HeLa cells expressing
Cx31.3, the human ortholog of Cx29 (Sargiannidou et al., 2008),
where oxaliplatin accelerated the uptake of neurobiotin through
hemichannels but this opening effect was reversed by octanol in a
concentration-dependent manner. Furthermore, oxaliplatin accel-
erated dye transfer between Cx32 expressing cells, and this effect
was again reversed by octanol.
Thus, oxaliplatin appears to uncouple and maintain open Cx32
channels and Cx29 hemichannels that would normally open only
brieﬂy during the passage of action potential, canceling the Kþ
siphoning mechanism. Excess extracellular Kþ in the narrow jux-
taparanodal region disrupts VGKC function and this appears in the
post-stimulus intra-axonal action potential as either a plateau or as
repetitive ﬁring (Kagiava et al., 2013). This gradual juxtaparanodal
accumulation of Kþ increasingly affecting VGKC function would
explain why the oxaliplatin-effect in this study and in all ourprevious experiments performed in rodent nerves using similar
oxaliplatin concentrations (Kagiava et al., 2008, 2013) occurs with a
delay, which is time- and concentration-dependent. In our exper-
iment with 25 mM oxaliplatin the development of the maximum
oxaliplatin-effect occurred within 300e360 min in nerves from
either WT or KO animals. At higher concentrations, 150 mM oxali-
platin, the same effect occurred within 50e60 min (Kagiava et al.,
2013). The model of oxaliplatin-induced uncoupling of connexin
channels proposed here for the peripheral nerve could also explain
in part the increased coupling of satellite cells in DRGs induced by
oxaliplatin, lowering pain threshold, which can also be antagonized
by GJ blockers (Warwick and Hanani, 2013), as well as the increased
coupling of spinal cord astrocytes leading to oxaliplatin-induced
mechanical hypersensitivity (Yoon et al., 2013).4.5. Morphological changes following prolonged oxaliplatin
exposure
Our electrophysiological studies show that nerve ﬁbers incu-
bated in 25 mM oxaliplatin develop within the ﬁrst 3e4 h a severe
increase in the RT of the CAP which reaches a maximum and per-
sists for the remaining of the 20 h incubation time. We then asked
whether there is an ultrastructural correlate to this oxaliplatin ef-
fect. Detailed morphological studies revealed that after the ﬁrst
300 min, when the electrophysiological alterations are fully
developed, there is no alteration in the ﬁne structure of the nerve
ﬁbers, focusing on perinodal areas. Thus, functional alterations in
our model precede any morphological changes, as also described in
the clinical setting (Lehky et al., 2004; Park et al., 2009). This fact
also excludes the possibility that oxaliplatin causes a primary
structural alteration or redistribution of VGKCs and associated
molecules or Cx29 hemichannels, that could then lead to
dysfunction of the peripheral nerve. However, with further oxali-
platin exposure for 1200minwe found characteristic axonal edema
in the juxtaparanodal areas, as shown by teased ﬁber and electron
microscopy examination. These changes occurred only in oxali-
platin treated ﬁbers that exhibited the CAP prolongation, but not in
control or in oxaliplatin þ octanol treated ﬁbers, again in line with
clinical data supporting that the early ﬁndings of hyperexcitability
are predictive of later development of neuropathy (Park et al.,
2009).
Despite the late morphological changes in the juxtaparanodal
areas due to axonal edema, the clustering of VGKCs in oxaliplatin-
exposed nerves was not disrupted (Poliak et al., 2003; Traka
et al., 2003), nor there was any diffusion of VGKCs into the para-
nodal areas (Boyle et al., 2001) as seen in mutants of axonal do-
mains. Furthermore, none of those mutants show the severe CAP
prolongation caused by oxaliplatin. Finally, we could not detect any
abnormalities in Naþ/Kþ ATPase subunit expression, in agreement
with previous electrophysiological studies showing a much
different functional effect of ATPase blockers on the sciatic nerve
compared to the oxaliplatin effect (Kagiava et al., 2012), indicating
that ATPase is not directly involved in OIN.
The edematous axonal changes following prolonged oxaliplatin
exposure are unique. We speculate that prolonged nerve exposure
to oxaliplatin and as a result the uncoupling and persistent opening
of Cx29 hemichannels and Cx32 GJs in the myelin sheath leads to
reversal of Kþ ﬂow from Schwann cell cytoplasm to the periaxonal
space. Gradual accumulation of Kþ in this narrow space and
cancellation of the activity-dependent siphoning function (above)
may also reverse cation ﬂow resulting in osmotic edema in the
axon. Similar mechanisms have been described in the CNS (Rash,
2010), where the collapse of Kþ homeostasis may lead to disrup-
tion of the restingmembrane potential, release of cytotoxic levels of
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and rupture (Quist et al., 2000).
4.6. Octanol as neuroprotectant against OIN in clinical practice
Numerous attempts to reduce OIN have been reported, using
goshajinkigan (Ushio et al., 2012), synthetic eel calcitonin and
elcatonin (Aoki et al., 2012), neurotropin (Kawashiri et al., 2011),
silibinin (Di Cesare Mannelli et al., 2012), minocycline (Boyette-
Davis and Dougherty, 2011), monosialotetrahexosyl ganglioside
(Chen et al., 2012), and calcium blockers (Tatsushima et al., 2013).
Similarly, ethosuximide (Flatters and Bennett, 2004) and neuro-
tropin (Kawashiri et al., 2009) were found to reverse paclitaxel-
induced peripheral neuropathy without affecting anti-tumor
efﬁcacy. This study clearly supports the potential for octanol to
efﬁciently prevent OIN by blocking Cx32 and Cx29 channels, which
are present in rodent peripheral nerves. This protective effect was
veriﬁed by our in vitro experiments in HeLa cells expressing either
of the two connexins. Thus, octanol can be used for medical
treatment since it was found to bewell-tolerated and safe in clinical
trials for essential tremor (Bushara et al., 2004; Haubenberger et al.,
2014). The optimal administration protocol will have to be devel-
oped, since for maximum protection we had to apply the two
compounds, octanol and oxaliplatin simultaneously. Nevertheless,
administration of octanol prior to oxaliplatin still provided a
marked neuroprotection. Octanol offers the advantage that it can be
used at very low concentrations (200 nM) against OIN, while for
other blockers such as GRA much higher concentrations (25 mM)
are required to offer a weaker protection. Although octanol offers
almost the same neuroprotection against OIN at low and high
concentrations, the lower concentrations appear to have almost no
side effects, reﬂected in CAP preservation. Further studies in in vivo
models of OIN will be needed to reproduce the ex vivo ﬁndings and
inform the best approach for future clinical trials as well.
Besides octanol we also studied three more GJ blockers, carbe-
noxolone, GRA and OA for the potential to offer protection against
OIN. Overall, they provided weaker or no protection at lower con-
centrations, over 125e1500 times higher than the corresponding
concentration for octanol, with little toxicity, whereas at higher
concentrations they were neurotoxic, eliminating the CAP. Thus,
carbenoxolone offered no protective effect at non-toxic concen-
trations (25 mM), while OA (300 mM) offered only a 37.6%
improvement in RT prolongation caused by oxaliplatin. GRA
(25 mM) showed a better proﬁle, offering a clear neuroprotective
effect of 78.8% at relatively non-toxic concentrations. Thus, GRA
largely reproduced the effects of octanol, but at much higher con-
centrations. Furthermore, oxaliplatin antagonized the negative
impact of GRA on the CAP, as we observed for octanol. This high
concentration may be deleterious when used in in vivo studies or in
clinical practice. The lack of protection by carbenoxolone may be
due to the fact that it has a number of other effects, including a
reduction in excitatory and inhibitory synaptic currents, alteration
of intrinsic membrane properties and suppression of action
potentials (Rouach et al., 2003; Tovar et al., 2009; Beaumont and
Maccaferri, 2011). Carbenoxolone has also been reported to block
Ca2þ channels, pannexin channels and P2X7 receptors at concen-
trations similar to or lower than those blocking connexin channels
(Vessey et al., 2004; Bruzzone et al., 2005; Suadicani et al., 2006).
Taken together, the results of testing further GJ blockers against OIN
conﬁrm the protective effect of blocking GJ channels. However,
octanol remains the best choice with the most favorable thera-
peutic window.
In conclusion, we provide a mechanistic explanation for OIN
based on uncoupling by oxaliplatin of Cx32 GJ channels and Cx29/
Cx31.3 hemichannels apposing VGKCs, leading to early functionalabnormalities promoting hyperexcitability, and to later morpho-
logical changes consisting of axonal juxtaparanodal edema.
Furthermore, the clinically relevant GJ blocker octanol effectively
prevents oxaliplatin effects ex vivo and in vitro and should be
further studied for the possibility of preventive use in OIN.
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